Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 48.25% | 28.19% | -29.11% | -11.72% | -20.71% |
| Total Depreciation and Amortization | 31.86% | 14.33% | 3.72% | 5.54% | 10.95% |
| Total Amortization of Deferred Charges | -18.08% | -23.79% | 7.41% | 4.85% | -6.76% |
| Total Other Non-Cash Items | -198.27% | -114.61% | 118.55% | 50.37% | 15.71% |
| Change in Net Operating Assets | -64.20% | 29.59% | 452.04% | 2,334.94% | 3,719.89% |
| Cash from Operations | 11.43% | 21.49% | 6.72% | 25.15% | 1.41% |
| Capital Expenditure | -77.42% | -48.32% | 50.00% | 59.69% | 62.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -113.25% | -78.99% | 27.03% | 59.69% | 62.95% |
| Total Debt Issued | -8.13% | -8.65% | -2.97% | -24.61% | 12.71% |
| Total Debt Repaid | 42.99% | 11.37% | -34.75% | -363.62% | -618.31% |
| Issuance of Common Stock | -12.63% | 22.79% | 85.03% | 424.98% | 604.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -98.38% | -68.58% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -100.00% | -100.00% |
| Cash from Financing | -17.06% | -13.13% | -6.47% | -14.84% | 7.98% |
| Foreign Exchange rate Adjustments | 254.57% | -245.48% | 133.90% | -386.82% | -205.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -429.90% | 1,665.31% | 151.33% | -1.51% | 108.11% |